# Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

> **NCT00671554** · PHASE1,PHASE2 · TERMINATED · sponsor: **Prisma Health-Upstate** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Melaxin (autologous dendritoma vaccine) and BCG

## Key facts

- **NCT ID:** NCT00671554
- **Lead sponsor:** Prisma Health-Upstate
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-02
- **Final completion:** 2009-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Due to business considerations; not due to toxicities or adverse events.
- **Last updated:** 2014-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671554, "Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00671554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*